1. First report on ototoxicity of meglumine antimoniate.
- Author
-
Valete-Rosalino CM, Araujo-Melo MH, Bezerra DC, Barcelos RO, Melo-Ferreira Vd, Torraca TS, Martins AC, Moreira JS, Vargas MC, Braga FP, Salgueiro Mde M, Saheki MN, and Schubach AO
- Subjects
- Aged, Audiometry, Pure-Tone, Humans, Leishmaniasis, Cutaneous drug therapy, Male, Meglumine Antimoniate, Severity of Illness Index, Antiprotozoal Agents adverse effects, Auditory Threshold drug effects, Dizziness chemically induced, Meglumine adverse effects, Organometallic Compounds adverse effects, Tinnitus chemically induced
- Abstract
Introduction: Pentavalent antimonials are the first drug of choice in the treatment of tegumentary leishmaniasis. Data on ototoxicity related with such drugs is scarcely available in literature, leading us to develop a study on cochleovestibular functions., Case Report: A case of a tegumentary leishmaniasis patient, a 78-year-old man who presented a substantial increase in auditory threshold with tinnitus and severe rotatory dizziness during the treatment with meglumine antimoniate, is reported. These symptoms worsened in two weeks after treatment was interrupted., Conclusion: Dizziness and tinnitus had already been related to meglumine antimoniate. However, this is the first well documented case of cochlear-vestibular toxicity related to meglumine antimoniate.
- Published
- 2014
- Full Text
- View/download PDF